TScan Therapeutics to Participate in Upcoming Investor Conferences
02 mars 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell...
TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies...
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies
24 janv. 2022 07h00 HE
|
TScan Therapeutics, Inc.
– Phase 1 trial of TSC-100 expected to initiate in the first half of 2022 – – IND for TSC-101 on hold pending additional assessment of the risk of off-tumor reactivity – WALTHAM, Mass., Jan. ...
TScan Outlines 2022 Priorities as Programs Enter Clinic
10 janv. 2022 07h00 HE
|
TScan Therapeutics, Inc.
IND Submissions Completed in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Candidates TSC-100 and TSC-101 Lead TCR Identified for Solid Tumor Program Targeting HPV16; Further TCRs Advancing into...
TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition
13 déc. 2021 09h16 HE
|
TScan Therapeutics, Inc.
- Posters highlight discovery of TSC-101, manufacturing process and clinical development plan for liquid tumor candidates TSC-101 and TSC-102 - - Phase 1 clinical trial expected to initiate in the...
TScan Therapeutics to Host a Virtual Event to Discuss Highlights from the 63rd ASH Annual Meeting and Exposition
03 déc. 2021 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies...
TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cell Therapies
02 déc. 2021 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies...
TScan Therapeutics to Participate in Upcoming Investor Conferences
11 nov. 2021 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies...
TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
10 nov. 2021 07h00 HE
|
TScan Therapeutics, Inc.
IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates TSC-100 and TSC-101 Lead TCR Identified for TSC-200 Solid Tumor Program Targeting HPV16; TCR Advancing...
TScan Therapeutics Announces Upcoming Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition
04 nov. 2021 09h30 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies...